New U.S. patent related to Oasmia Pharmaceutical’s nanotechnology platform XR17 has been granted
20 Novembre 2018 - 8:00AM
Oasmia Pharmaceutical AB (Nasdaq: OASM)
announces that the United States Patent and Trademark Office
(USPTO) has issued a notification of allowance of a patent for its
unique nanotech method to produce novel pharmaceutical
formulations. The patent will be published on November 27th,
2018.
The patent covers the method to characterize
Oasmia´s patented excipient XR17, that delivers human and animal
cancer drugs less invasive and more effectively. Thus, the patented
method is an advantageous substitute technology that contributes to
the development of competing drugs such as well-established cancer
treatments.
This novel character is due to lack of prior
inventions with the same features. This status has resulted in a
very quick patent filling process of less than two years. In
comparison, the 2017 new drug approvals median time in USA is of 14
years. The patent will be valid through 2036.
It is also important to note that, although the
granted patent is for a method of production, the products produced
by the method are also protected by the patent claims in accordance
with Article 64(2) of the European Patent Convention. The
functional claims of the patent have been partially or fully tested
by FDA (Food and Drug Administration) and EMA (European Medical
Agency).
The notification confirms the inventive nature
of the method, outlined in the patent application, both as a less
complex and a simpler method of production, as well as providing
and increasing yield at comparable reaction times when compared to
competing methods.
This event opens further the possibility to
develop new potential licensing revenues, to address alternative
markets and achieve further synergies in production, marketing and
sales.
For more information:Julian Aleksov,
Executive ChairmanTel: +46 18 50 54 40
E-mail: julian.aleksov@oasmia.com
Notes to editors:
About Oasmia Pharmaceutical AB Oasmia
Pharmaceutical AB develops, manufactures, markets and sells new
generations of drugs in the field of human and veterinary oncology.
The company’s product development aims to create and manufacture
novel nanoparticle formulations and drug-delivery systems based on
well-established cytostatics which, in comparison with current
alternatives, show improved properties, reduced side-effects, and
expanded applications. The company’s product development is based
on its proprietary in-house research and company patents. Oasmia is
listed on NASDAQ Capital Markets (OASM.US), Frankfurt Stock
Exchange (OMAX.GR, ISIN SE0000722365) and NASDAQ Stockholm
(OASM.ST).
Information is also available at www.oasmia.com
www.nasdaqomxnordic.com www.boerse-frankfurt.de
twitter.com/oasmia
This information is information that Oasmia
Pharmaceutical AB is obliged to make public pursuant to the EU
Market Abuse Regulation. The information was submitted for
publication, through the agency of the contact person set out
above, at 07.00 am EST on November 20, 2018.
Oasmia Pharmaceuticals AB (NASDAQ:OASM)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Oasmia Pharmaceuticals AB (NASDAQ:OASM)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024